EP1229930A4 - Compositions and methods for treatment of allergic disorders - Google Patents

Compositions and methods for treatment of allergic disorders

Info

Publication number
EP1229930A4
EP1229930A4 EP00975685A EP00975685A EP1229930A4 EP 1229930 A4 EP1229930 A4 EP 1229930A4 EP 00975685 A EP00975685 A EP 00975685A EP 00975685 A EP00975685 A EP 00975685A EP 1229930 A4 EP1229930 A4 EP 1229930A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
allergic disorders
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00975685A
Other languages
German (de)
French (fr)
Other versions
EP1229930A1 (en
Inventor
Robert Llewellyn Clancy
Gerald Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
PROBIALL Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROBIALL Pty Ltd filed Critical PROBIALL Pty Ltd
Publication of EP1229930A1 publication Critical patent/EP1229930A1/en
Publication of EP1229930A4 publication Critical patent/EP1229930A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/07Bacillus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866Interferon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/113Acidophilus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/125Casei
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
EP00975685A 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders Withdrawn EP1229930A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ415899 1999-11-19
AUPQ4158A AUPQ415899A0 (en) 1999-11-19 1999-11-19 Compositions for and methods of treatment of allergic diseases
PCT/AU2000/001414 WO2001037865A1 (en) 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders

Publications (2)

Publication Number Publication Date
EP1229930A1 EP1229930A1 (en) 2002-08-14
EP1229930A4 true EP1229930A4 (en) 2004-09-22

Family

ID=3818302

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00975685A Withdrawn EP1229930A4 (en) 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders

Country Status (9)

Country Link
EP (1) EP1229930A4 (en)
JP (1) JP2003514869A (en)
KR (1) KR20020084066A (en)
CN (1) CN1391480A (en)
AU (1) AUPQ415899A0 (en)
BR (1) BR0015698A (en)
CA (1) CA2391499A1 (en)
HK (1) HK1049115A1 (en)
WO (1) WO2001037865A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (en) 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
FI110668B (en) * 2000-06-20 2003-03-14 Aboatech Ab Oy Use of probiotics for primary prevention of atopic diseases
PE20030283A1 (en) * 2001-07-26 2003-05-01 Alimentary Health Ltd LACTOBACILLUS CASEI STRAINS
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
JP4212838B2 (en) 2002-06-26 2009-01-21 カルピス株式会社 Antiallergic agent
US20060088513A1 (en) * 2003-03-13 2006-04-27 Kirin Beer Kabushiki Kaisha Antiallergic composition
JP4712289B2 (en) * 2003-08-26 2011-06-29 株式会社エイ・エル・エイ Immune promoting composition
JP4591810B2 (en) * 2003-09-19 2010-12-01 日之出産業株式会社 Nasal composition for controlling hay fever allergic rhinitis
RU2407784C2 (en) * 2003-12-17 2010-12-27 Н.В. Нютрисиа Probiotic strain lactobacillus casei producing lactic acid, application of strain for preparing nutritinal composition for treatment or prevention of pulmonary dysfunction, nutritinal composition and method for preparing thereof, drug for treatment or prevention of chronic obstructive pulmonary disease in individual and application of strain for preparing drug, container
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
TWI356680B (en) * 2007-01-05 2012-01-21 Promd Biotech Co Ltd Anti-allergy lactic acid bacteria
CN102657260B (en) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 Antiallergic lactobacillus
CN101328468B (en) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 Antiallergic lactic acid bacteria
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
DK2244734T3 (en) 2008-02-01 2016-08-15 Murdoch Childrens Res Inst PROCEDURE FOR INDUCTION OF TOLERANCE ABOUT AN ALLERGY
CN103282028B (en) 2010-08-10 2016-04-27 R·P·舍勒科技有限责任公司 The method of the stable Gelseal of preparation containing microencapsulation probiotic bacteria
KR101311989B1 (en) * 2010-11-17 2013-09-26 주식회사한국야쿠르트 Products containing Lactobacillus casei HY7211 having immuno-regulatory and immuno-stimulatory functions as effective component
AU2019206205A1 (en) * 2018-01-12 2020-06-25 Gi Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof
CN111296842B (en) * 2020-02-14 2021-01-05 赵一鸣 Probiotic composition with anti-allergy effect
CN112375722B (en) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 Lactobacillus casei LC-12 for improving allergy, and product and application thereof
CN117085046A (en) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 Lactobacillus acidophilus LS001 metaplasia and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (en) 1978-08-07 1984-11-13 極東脂肪酸株式会社 Allergic reaction inhibitor
JPS5946491B2 (en) 1979-03-14 1984-11-13 極東脂肪酸株式会社 Asthma treatment agent
JPH07265064A (en) 1993-11-23 1995-10-17 Taketoshi Yamada Composition for improving enterobacterial flora
JPH092959A (en) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd Immuno-globulin e antibody production suppressant and antiallergic agent
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
JPH11199495A (en) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk Antiallergic agent using enteric capsule
IT1298918B1 (en) * 1998-02-20 2000-02-07 Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
JP4074006B2 (en) * 1998-06-24 2008-04-09 アサマ化成株式会社 Method for producing IgE antibody production inhibitor and food using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
BR0015698A (en) 2002-07-23
KR20020084066A (en) 2002-11-04
WO2001037865A1 (en) 2001-05-31
CN1391480A (en) 2003-01-15
JP2003514869A (en) 2003-04-22
EP1229930A1 (en) 2002-08-14
CA2391499A1 (en) 2001-05-31
HK1049115A1 (en) 2003-05-02
AUPQ415899A0 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
HK1049115A1 (en) Compositions and methods for treatment of allergic disorders
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
AU6919100A (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
NZ514044A (en) Herbal compositions and uses for the treatment of allergic reactions
EP1335736A4 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
PL373565A1 (en) Methods and compositions for treatment of immune dysfunction disorders
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
EP1440080A4 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
IL151403A0 (en) Compositions and methods for treatment of epilepsy
EP1315499A4 (en) Compositions and methods for the treatment of anorectal disorders
HUP0200466A3 (en) Lipoglycan compositions and methods of treating parasitic infections
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU3924500A (en) Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
EP1440165A4 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
AU1361201A (en) Methods and compositions for treatment of traumatic brain injury
AU1621501A (en) Methods and compositions for treatment of disease
AU2002360318A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805
EP1210094A4 (en) Herbal compositions and uses for the treatment of allergic reactions
AU2001263047A1 (en) Compositions and methods for treatment of proliferative disorders
EP1463832A4 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604
EP1439851A4 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040811

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DSM IP ASSETS B.V.

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061229

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049115

Country of ref document: HK